enVVeno Medical Corp
$ 10.61
4.57%
07 Aug - close price
- Market Cap 7,086,800 USD
- Current Price $ 10.61
- High / Low $ 11.15 / 10.61
- Stock P/E N/A
- Book Value 41.36
- EPS -26.11
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE -0.58 %
- 52 Week High 178.15
- 52 Week Low 8.67
About
enVVeno Medical Corp (NVNO) is a pioneering medical device firm focused on revolutionizing vascular access solutions for dialysis patients with its proprietary biocompatible technology. By aiming to fulfill essential unmet needs within the dialysis sector, the company enhances the safety and effectiveness of vascular procedures, positioning itself to capture significant growth in the vascular interventions market. With a strong commitment to advanced engineering and compliance with regulatory standards, enVVeno is well-aligned with the dynamic landscape of healthcare, underscoring its mission to elevate patient outcomes in this critical area.
Analyst Target Price
$30.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-07 | 2026-03-26 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-02-27 | 2024-10-30 | 2024-07-31 | 2024-05-08 | 2024-02-29 | 2023-10-26 |
| Reported EPS | -5.37 | -5.89 | -5.9092 | -0.23 | -11.55 | -0.22 | -10.5 | -12.25 | -10.85 | -10.85 | -0.36 | -15.75 |
| Estimated EPS | -4.69 | -8.4 | -0.28 | -0.3 | -9.8 | -0.34 | -12.25 | -11.55 | -12.6 | -14 | -0.46 | -16.8 |
| Surprise | -0.68 | 2.51 | -5.6292 | 0.07 | -1.75 | 0.12 | 1.75 | -0.7 | 1.75 | 3.15 | 0.1 | 1.05 |
| Surprise Percentage | -14.4989% | 29.881% | -2010.4286% | 23.3333% | -17.8571% | 35.2941% | 14.2857% | -6.0606% | 13.8889% | 22.5% | 21.7391% | 6.25% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NVNO
2026-08-04 19:11:46
A recently published health economic study in the Journal of Vascular Surgery demonstrates the economic dominance of enVVeno Medical's replacement venous valve therapy over standard care for deep venous CVI. The study projects significant healthcare savings, fewer venous ulcers, and improved quality of life for patients. These findings provide crucial evidence to support future reimbursement policies for enVVeno's non-surgical replacement venous valve therapy.
2026-08-04 17:40:48
A peer-reviewed study confirmed that enVVeno Medical's venous valve replacement therapy is economically dominant, projecting over $32,000 in savings per patient and approximately $5.9 billion in annual industry savings with broader adoption. This research supports future reimbursement efforts for their enVVe device by demonstrating significant healthcare savings and improved clinical outcomes compared to standard conservative care. The findings are particularly relevant for the company's next-generation non-surgical enVVe device, currently in the TAVVE pivotal trial, providing strong economic evidence for its therapeutic potential.
2026-08-04 12:39:25
A recently published health economic study in the Journal of Vascular Surgery found enVVeno Medical's VenoValve to be economically dominant over standard care for severe deep venous reflux. The analysis projected over $32,000 in average healthcare savings and approximately 2.2 fewer venous ulcers per patient over five years. These findings provide strong support for the company's investigational enVVe system, currently in the TAVVE pivotal trial, and suggest potential annual system-wide savings of around $5.9 billion with broader adoption of such therapies.
2026-08-04 12:39:25
A recently published health economic study in the Journal of Vascular Surgery demonstrates that enVVeno Medical's replacement venous valve therapy is economically dominant over standard-of-care treatments for deep venous CVI. The study projects significant healthcare savings per patient, reduced venous ulcers, and improved quality-adjusted life years over five years. These findings provide crucial economic support for enVVeno's next-generation enVVe device, which is currently undergoing a pivotal trial, and suggest potential for substantial annual healthcare savings with broader adoption.
2026-08-01 03:40:48
enVVeno Medical announced its second quarter 2026 financial results, highlighting the FDA IDE approval for its TAVVE pivotal trial. This trial will evaluate the enVVe System, a non-surgical venous valve replacement for severe deep chronic venous insufficiency, with patient enrollment expected to begin in the second half of 2026. The company reported approximately $29.5 million in cash and investments, extending its cash runway into the third quarter of 2027.
2026-07-31 12:40:15
enVVeno Medical announced its second-quarter 2026 financial results, highlighted by FDA IDE approval for its TAVVE® pivotal trial. The company is set to begin enrolling patients for this non-surgical replacement venous valve study in the second half of 2026, with a cash runway extending into the third quarter of 2027. This progress aims to address severe deep chronic venous insufficiency, a condition currently lacking effective treatment options.
